Lecture 5 - Dementia

Global Demographics and Population Ageing

  • Demographic Transitions and Longevity Trends:

    • Global populations are undergoing a pronounced demographic shift toward increased longevity, characterized by rising overall life expectancies.

    • Falling birth and fertility rates worldwide have inverted historical demographic pyramids, concentrating a larger proportion of national populations in older age categories.

    • A significantly higher percentage of the human lifespan is now spent in advanced old age.

    • The expansion of the geriatric demographic is accompanied by a heightened prevalence of chronic non-communicable illnesses, including progressive neurodegenerative disorders and psychiatric conditions (Mathers et al., 2015, The Lancet).

    • A systematic understanding of age-related neurological and biological pathologies is essential to developing effective clinical interventions and healthcare management paradigms.

  • Historical and Projected Demographic Pyramids:

    • Demographic data from official registries (such as ons.gov.uk) highlight the structural transition of populations over a centennial arc:

    • 19661966 Cohort: A traditional pyramidal structure exhibiting a broad foundational base representing high infant and youth demographics, tapering smoothly toward a narrow apex above age 6565.

    • 20162016 Cohort: A transitional, barrel-shaped distribution resulting from the "baby boom" generation entering late midlife (ages 5050 to 7070), combined with declining youth birth rates.

    • 20662066 Projection: A top-heavy, columnar-to-inverted distribution where individuals aged 6565 to 90+90+ represent one of the largest proportions of the total living population, with cohorts exceeding 1,000,0001{,}000{,}000 individuals per age stratum in advanced years.

Age-sex population structures comparing 1966, 2016, and projected 2066 demographics

Defining Ageing: Chronological, Functional, Primary, and Secondary

  • Chronological versus Functional Age:

    • Chronological Age: Defined strictly as the elapsed time measured from birth using standard astronomical or calendar metrics; it serves as a uniform metric applied identically across all individuals.

    • Functional Age: Quantifies an individual's actual physiological, biological, and psychological operational capacity relative to normative population baselines.

    • Chronological age does not exhibit an absolute or perfect correlation with functional age. Individuals of identical chronological age can show drastically disparate cellular, cognitive, and functional profiles.

  • Primary Ageing (Senescence):

    • Universal, intrinsic, and progressive decline in biological and physiological functioning that eventually affects all members of a species.

    • Unfolds independently of overt pathology; it occurs across the lifespan within the context of overall "normal" health.

    • Represents basal biological senescence across cell, tissue, and organ systems.

  • Secondary Ageing:

    • Pathological or accelerated functional decline driven by hereditary defects, acquired systemic diseases, and adverse environmental or behavioral factors.

    • Modulating influences include poor dietary regimens, physical inactivity, substance or drug abuse, prolonged psychological stress, and environmental toxin/pollution exposure.

    • Bifurcates older adult populations into two distinct functional cohorts:

    • Those navigating late life with "normal" health (experiencing predominantly primary senescence).

    • Those experiencing "compromised" health secondary to clinical diseases or chronic abnormal medical states.

Cellular and Molecular Mechanisms of Biological Ageing

  • Biological Senescence at the Cellular Level:

    • Biological ageing reflects the cumulative damage and functional decline imposed by time across all physiological strata, from subcellular organelles to systemic physiology.

    • Somatic cells exhibit finite proliferative lifespans, entering replicative senescence determined by the cumulative number of mitotic divisions they have undergone.

    • Normal diploid human somatic cells are bounded by the Hayflick limit, dividing approximately 5050 times before their genetic machinery can no longer sustain fidelity in replication.

  • Telomere Biology and Replicative Exhaustion:

    • Replicative senescence is fundamentally governed by the shortening of telomeres, which are non-coding nucleoprotein caps located at the terminal ends of eukaryotic chromosomes (Shay, 2018; Vaziri et al., 1993).

    • Human telomeric DNA consists of repetitive tandem hexanucleotide sequences:

    • Composed of 66 base pairs:       5’-TTAGGG-3’\text{5'-TTAGGG-3'}       bound to the complementary strand:       3’-AATCCC-5’\text{3'-AATCCC-5'}

    • Repeated thousands of times at each chromosomal terminus.

    • The "end-replication problem" inherent to DNA polymerase prevents complete synthesis of the extreme 3′3' ends of linear chromosomes during lagging-strand synthesis.

    • Consequently, each mitotic division results in progressive telomeric attrition until a critically shortened threshold is reached, triggering permanent cell-cycle arrest (senescence) or programmed cell death.

Diagram of telomere shortening during sequential rounds of cellular division
  • Cellular Replication, Damage, and Mitotic Vulnerabilities:

    • Cellular injury, chronic inflammation, and environmental assaults demand accelerated cell division to repair and regenerate compromised tissues.

    • Heightened proliferative rates deplete remaining telomeric reserves, hastening replicative exhaustion or predisposing cells to oncogenic mutations and tumor formation.

    • Severely damaged cells that fail internal repair checkpoints trigger self-destruction pathways to prevent malignant transformation.

    • Post-Mitotic Specificity of Neurons:

    • Mature central nervous system (CNS) neurons reside in a permanent, post-mitotic G0G_0 phase and do not undergo cell division or self-replacement through standard mitosis.

    • Because somatic replacement is absent, individual neurons must survive for the lifetime of the organism.

    • Neurons depend on neuroprotective support provided by surrounding glial cells (astrocytes, microglia, and oligodendrocytes) to shield them from metabolic exhaustion, excitotoxicity, and environmental insults.

Neurodegeneration: Triggers, Proteinopathies, and Modes of Neuronal Death

  • Characteristics of Neurodegenerative Disease:

    • Neurodegeneration is defined as the slow, progressive, and irreversible loss of neuronal structure, synaptic connectivity, and physiological function.

    • Leads to chronic structural collapse of specialized neural circuits and broad functional deterioration.

Comparison of gross cerebral morphology between a healthy brain and a brain affected by Creutzfeldt-Jakob Disease
  • Pathogenic Triggers of Neuronal Death:

    • Oxidative Stress: Generated when reactive oxygen species (ROS) and free radicals overwhelm endogenous cellular antioxidant defenses, inducing lipid peroxidation of neuronal membranes, protein cross-linking, and mitochondrial DNA damage.

    • Lifestyle and Environmental Exposures: Systemic neurotoxins, alcohol abuse, chronic pharmacological exposures, and sustained stress.

    • Neuroinflammation: Chronic microglial and astrocytic activation, often initiated by systemic or CNS infection, releasing neurotoxic cytokines and chemokines.

    • Glutamate Excitotoxicity: Excessive, unregulated synaptic release or compromised reuptake of the excitatory neurotransmitter glutamate, leading to overactivation of NN-methyl-DD-aspartate (NMDA) receptors, massive intracellular calcium (Ca2+\text{Ca}^{2+}) influx, mitochondrial failure, and enzymatic digestion of cellular architecture.

Cellular progression of free radical attack leading to oxidative stress
  • Toxic Protein Aggregations (Proteinopathies):

    • Prions: Conformational conversion of normal cellular prion protein (PrPC\text{PrP}^C) into abnormal, self-propagating, protease-resistant scrapie isoforms (PrPSc\text{PrP}^{Sc}), causing rapid, spongiform cerebral encephalopathy.

    • Beta-Amyloid (Aβ\text{A}\beta): Pathological misfolding and aggregation of hydrophobic peptides into extracellular diffuse and fibrillar senile plaques.

    • Hyperphosphorylated Tau: Microtubule-associated protein tau undergoes pathological enzymatic hyperphosphorylation, precipitating intracellular neurofibrillary tangles (NFTs).

    • Alpha-Synuclein (α\alpha-synuclein): Abnormal intracellular protein aggregates coalescing into inclusions termed Lewy bodies, characteristic of Parkinson's disease and Lewy body dementias.

Intracellular Lewy body inclusion located within the neuronal cytoplasm
  • Pathological Pathways of Neuronal Elimination:

    • Necrosis:

    • Unregulated, passive form of cell death triggered by acute injury, severe metabolic depletion, or direct toxic exposure.

    • Characterized by bioenergetic failure, loss of membrane potential, cellular and organellar swelling (oncosis), and membrane lysis.

    • Rupture causes uncontrolled release of intracellular contents into the extracellular milieu, provoking secondary local inflammation.

    • Apoptosis:

    • Regulated, programmed cell death orchestrated through intrinsic (mitochondrial) or extrinsic (death receptor) caspase-dependent cascades.

    • Initiated by cell-autonomous checkpoints or exposure to pro-apoptotic signaling molecules.

    • Characterized by cell shrinkage, cytoplasmic condensation, nuclear chromatin pyknosis/karyorrhexis, membrane blebbing, and orderly packaging into apoptotic bodies.

    • Apoptotic remnants are cleared via phagocytosis without releasing inflammatory mediators or injuring neighbouring neural parenchyma.

Morphological distinction between necrotic swelling/lysis and apoptotic condensation/fragmentation

Autonomic Nervous System & Peripheral Physiological Alterations

  • Age-Associated Changes in the Autonomic Nervous System (ANS):

    • Progressive dysregulation between the sympathetic and parasympathetic branches impairs homeostatic control across multiple organ systems.

    • Basal cardiovascular alterations manifest as resting elevations in systolic blood pressure and vascular resistance.

    • Blunted sympathetic nerve activation dynamics lead to reduced baroreflex sensitivity and impaired hemodynamic responsiveness to orthostatic challenges.

    • Endocrine deregulation leads to basal hypersecretion of cortisol via hypothalamic-pituitary-adrenal (HPA) axis disinhibition.

    • Escalation of chronic low-grade inflammatory signaling in peripheral tissues (inflammaging).

    • Structural remodeling and functional breakdown at the neuromuscular junction (NMJ), driving motor unit loss and skeletal muscle weakness (sarcopenia).

Anatomical pathways and peripheral organ innervation of the autonomic nervous system
  • Clinical and Quality-of-Life Correlates:

    • Autonomic impairment significantly affects subjective health and mood states in geriatric cohorts.

    • Empirical findings show that autonomic symptoms in older adults account for:

    • Approximately 20%20\% of the variance in Health-Related Quality of Life (HRQoL) measures.

    • Approximately 32%32\% of the variance in depressive mood presentations (Renno-Busch et al., 2021, Frontiers in Neurology).

Macrostructural and Microstructural Brain Changes in Ageing

  • Macrostructural Cerebral Remodeling:

    • Typical ageing induces progressive cerebral atrophy characterized by widening and deepening of cortical sulci alongside narrowing of adjacent cortical gyri.

    • Enlargement of the internal ventricular cavities (lateral and third ventricles) occurs secondary to parenchymal volume loss (hydrocephalus ex vacuo).

    • Global reductions across both cerebral grey matter (neuronal somas and dendritic arborizations) and cerebral white matter (axonal bundles and oligodendrocytic myelin sheaths).

    • Healthy individuals lose an average of approximately 100 g100\,\text{g} of brain tissue over an adult lifespan, representing a 7%7\% total cerebral volume reduction.

    • Neuroimaging demonstrates a progressive decline in neural processing speed and network efficiency spanning from adolescence through late adulthood (Statsenko et al., 2022, Frontiers in Aging Neuroscience).

Longitudinal structural MRI cross-sections from adolescence to late adulthood
  • Microstructural Degradation and Cognitive-Motor Phenotypes:

    • Microstructural white matter tract integrity is quantified using Diffusion Tensor Imaging (DTI) metrics:

    • Fractional Anisotropy (FA): Reflects the directional coherence of water diffusion along intact, myelinated axonal tracts; decreases denote demyelination or axonal loss.

    • Mean Diffusivity (MD): Quantifies the overall molecular displacement of water molecules; increases denote structural breakdown and expanding extracellular fluid compartments.

    • Older adults fall into discrete longitudinal functional trajectories (Grande et al., 2023, J Gerontol A Biol Sci Med Sci):

    • Slow/No Decliners: Maintain stable cognitive and motor performance, accompanied by stable DTI metrics.

    • Isolated Motor Decliners: Show selective motor slowing with targeted tract degradation.

    • Isolated Cognitive Decliners: Exhibit selective cognitive impairments linked to specific association tract disruption.

    • Cognitive and Motor Decliners: Exhibit the steepest, most widespread structural degradation, with the largest increases in mean diffusivity and severe drops in fractional anisotropy.

Mean diffusivity changes across cognitive and motor decliner subgroups
  • Longitudinal Structural Markers:

    • Longitudinal monitoring across multi-year follow-up intervals (00 to 6 years6\,\text{years}) demonstrates divergence among functional subgroups:

    • Hippocampal Volume Loss: Accelerated hippocampal decline is most severe in combined cognitive-motor decliners (dropping from baseline values of ∼7.3 mL\sim 7.3\,\text{mL} down to $< 5.0\,\text{mL}), followed by isolated cognitive decliners, isolated motor decliners, and slow/no decliners.\n - **Total Brain Tissue Volume:** Continuous descent over 6\,\text{years},droppingfrombaselinelevels(, dropping from baseline levels (\sim 1050\,\text{mL}toto1070\,\text{mL}) to $< 850\,\text{mL} in severe decliners.

    • White Matter Hyperintensities (WMH): Progressive accumulation of ischemic leukoaraiosis lesions, measured in milliliters (mL\text{mL}), expanding rapidly in combined cognitive and motor decliners from ∼9.5 mL\sim 9.5\,\text{mL} past 24.0 mL24.0\,\text{mL} over 6 years6\,\text{years}.

Longitudinal trajectories of hippocampal volume loss over six years across decliner profiles

The Cholinergic System and Glucocorticoid Stress Interactions

  • The Central Cholinergic System in Senescence:

    • The ascending cholinergic projection system, utilizing acetylcholine (ACh) as its primary neurotransmitter, plays a critical regulatory role in cellular ageing, cortical activation, attention, and memory encoding (Lee & Kim, 2022).

    • Magnocellular cholinergic neurons within the basal forebrain complex (including the nucleus basalis of Meynert, medial septal nuclei, and vertical diagonal band of Broca) are consistently among the earliest neural populations compromised in progressive degenerative conditions (Schliebs & Arendt, 2011).

    • Cholinergic basal forebrain degeneration occurs across multiple neurological disorders, including:

    • Parkinson's Disease (PD)

    • Down Syndrome

    • Progressive Supranuclear Palsy (PSP)

    • Creutzfeldt-Jakob Disease (CJD)

    • Wernicke-Korsakoff Syndrome

    • Traumatic Brain Injury (TBI)

    • Alzheimer's Disease (AD)

    • Direct loss of cholinergic innervation to the hippocampus and neocortex produces marked episodic memory encoding and retrieval failures in the ageing brain.

Ball-and-stick molecular model of acetylcholine
  • Glucocorticoids and Hippocampal Morphology:

    • Elevated systemic cortisol levels, driven by age-related HPA-axis hyperactivity and psychological stress, target high-density glucocorticoid and mineralocorticoid receptors in the hippocampus.

    • Chronic hypercortisolemia induces dendritic branch retraction and synaptic spine loss in CA3 and CA1 pyramidal neurons.

    • Suppresses adult neurogenesis and neural progenitor cell proliferation within the subgranular zone of the dentate gyrus.

    • Accelerates global hippocampal volumetric atrophy, reinforcing age-related memory deterioration (Kim, Pellman, & Kim, 2015).

Ball-and-stick molecular model of cortisol

Cognitive Profiles: Normal Healthy Ageing vs. Alzheimer's Pathology

  • Cognitive Characteristics of Healthy Aging:

    • Healthy biological ageing produces subtle, circumscribed cognitive changes rather than generalized intellectual collapse (Harada, Love, & Triebel, 2013).

    • Young adults typically demonstrate:

    • Sharper sensory acuity (visual and auditory discrimination thresholds).

    • Faster psychomotor reaction times and raw mental processing speed.

    • Greater working memory capacity.

    • Superior learning efficiency on tasks requiring high perceptual speed, novel physical coordination, and motor stamina.

    • In healthy older adults free of underlying neuropathology, cognitive shifts are generally mild and domain-specific.

  • Cognitive Domain Divergence in Healthy Old Age:

    • Cognitive Domains that Decline with Age:

    • Delayed Free Recall: Spontaneous retrieval of stored episodic information without external prompts or cues (e.g., reciting a list of grocery items without a reference sheet).

    • Source Memory: Remembering the specific contextual origin of learned material (e.g., determining whether a medical fact was heard on television, read in print, or conveyed by an acquaintance).

    • Prospective Memory: Remembering to perform an intended action at a future time or event (e.g., remembering to take prescribed medication before going to bed).

    • Cognitive Domains that Remain Stable with Age:

    • Recognition Memory: Cued retrieval prompted by external environmental stimuli (e.g., identifying accurate story elements on a forced-choice yes/no test).

    • Temporal Order Memory: Preserved sequencing of past episodic events (e.g., remembering that a trip to the supermarket occurred immediately following lunch with friends last weekend).

    • Procedural Memory: Non-declarative memory encoding motor routines and implicit behavioural sequences (e.g., riding a bicycle or playing an instrument).

Alzheimer's Disease: Pathology, Epidemiology, and Clinical Staging

  • Clinical Definition and Hallmarks:

    • Alzheimer's Disease (AD) is a progressive neurodegenerative disease and the most prevalent form of clinical dementia among older adults.

    • Clinically manifests with an insidious onset of anterograde episodic memory loss, followed by multi-domain deterioration in abstract reasoning, executive planning, expressive and receptive language (aphasia), visuospatial processing (agnosia), motor praxis (apraxia), and mood stability (e.g., major depressive presentations).

    • Neuropathologically defined by gross cerebral atrophy, severe loss of cholinergic projection systems, and post-mortem confirmation of two hallmark protein lesions:

    • Extracellular senile plaques composed of insoluble beta-amyloid (Aβ\text{A}\beta).

    • Intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau.

Gross coronal cross-sections comparing healthy 70-year-old brain and Alzheimer's disease brain
  • Epidemiology and Age-Specific Prevalence:

    • The single greatest risk factor for AD is advancing chronological age (Qiu, Kivipelto, & von Strauss, 2009):

    • Worldwide Prevalence (≥60 years\ge 60\,\text{years}): Approximately 3.9%3.9\%.

    • European Prevalence (≥65 years\ge 65\,\text{years}): Approximately 4.4%4.4\%.

    • Cohort Prevalence (>70 years> 70\,\text{years}): Reaches 7.7%7.7\%.

    • Cohort Prevalence (≥85 years\ge 85\,\text{years}): Approaches approximately 50%50\% of all surviving individuals.

    • Reductions in mortality from infectious and cardiovascular diseases after age 6565 allow a larger segment of the global population to survive into advanced old age, where AD incidence rises exponentially.

    • Cohort studies across Europe (20002000), USA (20072007), China (20072007), and Brazil (20082008) confirm an exponential climb in prevalence per 100100 population beginning around ages 7575 to 7979 and peaking past age 9090.

Prevalence of Alzheimer's disease per 100 population across age brackets in international cohorts
  • Diagnostic Procedures during Life:

    • Definitive histopathological confirmation is only possible post-mortem via autopsy tissue analysis.

    • Clinical diagnosis during life is designated as "Probable AD" via exclusionary assessment, comprising:

    • Multimodal neuroimaging (structural MRI/CT detecting localized hippocampal and cortical atrophy; FDG-PET imaging highlighting biparietal and temporal hypometabolism).

    • Formal psychiatric and neurological medical histories.

    • Comprehensive physical examinations.

    • Standardized psychometric evaluations, prominently the Mini-Mental State Examination (MMSE).

FDG-PET metabolic imaging comparing normal cognition, mild cognitive impairment, and Alzheimer's disease
  • Anatomical and Chronological Stages of AD:

    • Mild Cognitive Impairment (MCI):

    • Duration: Approximately 7 years7\,\text{years}.

    • Anatomical Localization: Originates within the medial temporal lobe (transentorhinal cortex, entorhinal cortex, and hippocampus).

    • Clinical Profile: Subtle short-term memory encoding difficulties that exceed expectations for normal primary senescence without eliminating basic functional independence.

    • Mild Alzheimer's Disease:

    • Duration: Approximately 2 years2\,\text{years}.

    • Anatomical Localization: Spreads laterally into the lateral temporal and parietal lobes.

    • Clinical Profile: Worsening short-term memory deficits, spatial disorientation, language retrieval difficulties (anomia), and impaired financial/task management.

    • Moderate Alzheimer's Disease:

    • Duration: Approximately 2 years2\,\text{years}.

    • Anatomical Localization: Infiltrates the frontal lobes.

    • Clinical Profile: Severe executive dysfunction, impaired judgment, emotional blunting, personality alterations, behavioral disinhibition, and prominent paranoia or wandering.

    • Severe Alzheimer's Disease:

    • Duration: Approximately 3 years3\,\text{years}.

    • Anatomical Localization: Terminal infiltration into the occipital lobe and basic sensory-motor cortices.

    • Clinical Profile: Visual agnosia, loss of motor control and gait stability, complete urinary/fecal incontinence, loss of communicative speech, and total dependence requiring around-the-clock nursing care.

Anatomical progression and typical durations of the four clinical stages of Alzheimer's disease

The Amyloid Cascade Hypothesis and Plaque Pathogenesis

  • The Amyloid Hypothesis Framework:

    • The amyloid cascade hypothesis posits that an imbalance between the production and clearance of beta-amyloid (Aβ\text{A}\beta) peptides is the initiating trigger of AD.

    • Aberrant metabolism of Amyloid Precursor Protein (APP) yields toxic Aβ\text{A}\beta monomers that aggregate into oligomers, protofibrils, and insoluble senile plaques.

    • These aggregates induce downstream tau hyperphosphorylation, neurofibrillary tangle formation, neuroinflammation, synaptic loss, and neuronal death.

  • APP Biology and Enzymatic Cleavage:

    • APP is an integral type-I transmembrane glycoprotein concentrated at neuronal synapses, where it supports synapse formation, neural plasticity, and cell adhesion.

    • Generation of the amyloidogenic Aβ\text{A}\beta peptide requires sequential proteolysis of APP by two specific enzymes:

    • β\beta-Secretase (BACE1): Cleaves APP at an extracellular site, shedding the soluble sAPPβs\text{APP}\beta ectodomain and leaving the membrane-bound 99-amino acid C-terminal fragment (CTFβ\text{CTF}\beta or C99C99).

    • γ\gamma-Secretase: An intramembranous multimeric enzyme complex that cleaves the remaining C99C99 fragment within the lipid bilayer.

    • This sequential cleavage releases hydrophobic Aβ\text{A}\beta fragments of variable length, primarily Aβ1−40\text{A}\beta_{1-40} and the longer, more aggregation-prone Aβ1−42\text{A}\beta_{1-42}.

Proteolytic cleavage of amyloid precursor protein by beta-secretase and gamma-secretase
  • Mechanisms of Aβ\text{A}\beta Synaptic Toxicity:

    • Monomeric Aβ\text{A}\beta is hydrophobic and self-assembles into soluble oligomers (dimers, trimers, and higher-order complexes).

    • Soluble Aβ\text{A}\beta dimers and oligomers lodge at synaptic clefts, impairing long-term potentiation (LTP), inducing long-term depression (LTD), and disrupting neurotransmission (Russell et al., 2012).

    • Fibrillar Aβ\text{A}\beta coalesces into extracellular senile (amyloid) plaques that disrupt local neuropil architecture.

    • Presence of Aβ\text{A}\beta oligomers alters signal transduction pathways, driving kinases that catalyze the hyperphosphorylation of intracellular tau proteins.

Extracellular beta-amyloid plaque fibril aggregation

Tau Pathology, Microtubule Disassembly, and Neurofibrillary Tangles

  • Normal Function of Tau Protein:

    • Tau is a soluble, microtubule-associated protein enriched in the axonal compartments of neurons.

    • In healthy states, tau binds to tubulin heterodimers, stabilizing the longitudinal microtubule tracks that maintain axonal structure and support anterograde and retrograde transport of organelles, vesicles, and neurotrophic factors.

  • Hyperphosphorylation and Cytoskeletal Collapse:

    • In AD, pathological kinase activity overwhelms phosphatases, driving tau hyperphosphorylation.

    • Hyperphosphorylated tau undergoes conformational distortion, detaching from the microtubule polymer.

    • Loss of stabilizing tau causes microtubules to disintegrate into individual tubulin subunits, halting axonal transport.

    • Free hyperphosphorylated tau molecules misfold, cross-link, and coalesce into paired helical filaments (PHFs), which assemble into insoluble intracellular Neurofibrillary Tangles (NFTs).

    • Because tangle accumulation correlates directly with neuronal loss and cognitive decline, AD is classified as a canonical tauopathy (Sergeant et al., 2002, J Neurochem).

Tau hyperphosphorylation, microtubule collapse, and neurofibrillary tangle formation

Genetics of Alzheimer's Disease: Causative and Susceptibility Loci

  • The Apolipoprotein E (ApoE) Susceptibility Locus:

    • The APOE gene on chromosome 1919 encodes apolipoprotein E, a lipid-carrier glycoprotein that coordinates lipid metabolism, cholesterol transport, and membrane repair in the brain.

    • ApoE aids in the enzymatic degradation and clearance of Aβ\text{A}\beta peptides from the extracellular space.

    • Three polymorphic alleles (ε2\varepsilon2, ε3\varepsilon3, ε4\varepsilon4) define major clinical phenotypes:

    • ApoE-ε2\text{ApoE-}\varepsilon2 (7%7\% population frequency): Rare allele associated with reduced risk of AD; however, it confers susceptibility to type III hyperlipoproteinemia, peripheral atherosclerosis, and Parkinson's disease.

    • ApoE-ε3\text{ApoE-}\varepsilon3 (79%79\% population frequency): The wild-type, "neutral" allele that serves as the general baseline for population risk.

    • ApoE-ε4\text{ApoE-}\varepsilon4 (14%14\% population frequency): The strongest established genetic risk factor for late-onset sporadic AD.

    • The ApoE-ε4\varepsilon4 protein isoform binds Aβ\text{A}\beta with lower clearance efficiency, accelerating Aβ\text{A}\beta accumulation and lowering the age of symptom onset.

Ribbon structure representation of Apolipoprotein E
  • Early-Onset Familial AD (FAD) and Presenilins:

    • Early-onset autosomal dominant AD is caused by high-penetrance mutations in genes regulating the production of Aβ1−42\text{A}\beta_{1-42}:

    • APP gene on chromosome 2121.

    • Presenilin 1 (PSEN1) on chromosome 1414.

    • Presenilin 2 (PSEN2) on chromosome 11.

    • Presenilin proteins constitute the catalytic core of the intramembranous γ\gamma-secretase enzyme complex.

    • Pathogenic presenilin mutations shift cleavage precision, increasing the ratio of hydrophobic Aβ1−42\text{A}\beta_{1-42} relative to Aβ1−40\text{A}\beta_{1-40}.

    • Transgenic Knockout Findings:

    • Transgenic mouse models designed to inhibit γ\gamma-secretase successfully lowered Aβ\text{A}\beta plaque burden.

    • However, treated mice still developed profound neurodegeneration and toxic side effects, confirming that the γ\gamma-secretase enzyme regulates other essential physiological substrates, such as the Notch signaling receptor.

Pharmacological Interventions and Therapeutics

  • Current Therapeutic Landscape:

    • Pharmacological agents provide symptomatic cognitive and functional stabilization, but they do not arrest or reverse underlying neurodegeneration.

    • Novel therapeutics in development include monoclonal antibody immunotherapies and anti-amyloid vaccines designed to clear cerebral plaques.

  • Cholinesterase Inhibitors (AChEIs):

    • Mechanism of Action: Block the acetylcholinesterase enzyme from hydrolyzing acetylcholine within the synaptic cleft, elevating cholinergic neurotransmission across neocortical and hippocampal networks while potentially reducing Aβ\text{A}\beta deposition.

    • Key Compounds:

    • Tacrine: First-generation inhibitor; now obsolete due to severe dose-dependent hepatotoxicity.

    • Donepezil: Highly selective, reversible, piperidine-based acetylcholinesterase inhibitor with long elimination kinetics.

    • Rivastigmine: Pseudo-irreversible carbamate inhibitor that targets both acetylcholinesterase and butyrylcholinesterase.

    • Galantamine: Phenanthrene alkaloid that acts as a competitive acetylcholinesterase inhibitor and allosteric potentiator of nicotinic acetylcholine receptors.

    • Physostigmine: Reversible natural cholinesterase inhibitor used largely in early investigative pharmacology.

    • Metrifonate: Organophosphate prodrug that non-enzymatically converts to the active inhibitor dichlorvos.

    • Clinical Efficacy: Consistently show statistically significant improvements in MMSE scores, functional autonomy, and behavioral indices over placebo in mild-to-moderate AD. Clinical effect sizes are generally modest, and disease progression resumes as underlying neuron loss continues.

  • NMDA Receptor Antagonists (Memantine):

    • Mechanism of Action: Voltage-dependent, low-to-moderate affinity, uncompetitive antagonist at glutamate NMDA receptor channels.

    • Functional Role: Blocks pathological tonic baseline activation driven by excess glutamate, suppressing chronic calcium influx and excitotoxicity while preserving the transient, high-amplitude signaling required for physiological synaptic transmission.

    • Formulations and Indications: Marketed under brand names including Axura, Akatinol, Abixa, Memox, and Namenda. Approved for the clinical management of moderate-to-severe AD, providing modest stabilization of cognitive and functional endpoints.

Ball-and-stick molecular structure of memantine

Cognitive Reserve, Lifestyle Factors, and Non-Pharmacological Strategies

  • The Concept of Cognitive Reserve:

    • Cognitive reserve describes the capacity of the brain to tolerate neuropathological damage without displaying overt clinical functional decline (Franzmeier et al., 2017).

    • Characterized by individual variability in the recruitment of alternative neural networks and cognitive processing strategies to compensate for progressive brain injury.

    • Modeled statistically using residualized memory metrics, plotting actual memory performance against memory performance predicted by hippocampal volume, chronological age, and biological sex:

    • Individuals performing above their structural prediction line demonstrate high cognitive reserve.

    • Individuals performing below their structural prediction line demonstrate lower cognitive reserve.

Linear regression model illustrating cognitive reserve via residualized memory performance
  • Protective Factors and Empirical Validation:

    • Educational Attainment and Intellectual Complexity: Higher lifetime educational attainment and occupational intellectual stimulation build synaptic density and network resilience, delaying the clinical onset of dementia symptoms.

    • Physical Exercise: Structured aerobic physical activity lowers Aβ\text{A}\beta levels and elevates brain-derived neurotrophic factor (BDNF) in transgenic mouse models, buffering the brain against stress-induced cellular damage and atrophy (Um et al., 2008).

    • Commercial "Brain Training" Games: Software programs (e.g., Lumosity, Nintendo DS) lack robust empirical evidence demonstrating transfer of training to generalized real-world cognitive functioning or prevention of neurodegenerative pathology (Owen et al., 2010).

    • Social and Leisure Engagement: Ongoing participation in structured social and leisure pursuits correlates with maintained cognitive vitality into advanced old age.

Recommended References and Core Literature

  • Essential Curricular Reading:

    • Carlson, N.R., & Birkett, M.A. Physiology of Behavior (13th Edition, 2022 / Chapter 15, 2017 & Chapter 16, 2022: "Degenerative Disorders"). Pearson.

  • Specialized Monographs and Extended Literature:

    • Cabeza, R., Nyberg, L., & Park, D.C. (Eds.). (2016). Cognitive Neuroscience of Aging: Linking Cognitive and Cerebral Aging (2nd ed.). Oxford University Press. Chapters 1, 2, 5, 6, 11, 14, 16, & 19.

    • Getz, G.E. (2014). Applied Biological Psychology. Springer Publishing Company. Chapter 12, pp. 176–182.

    • Reitz, C. (2012). Alzheimer's disease and the amyloid cascade hypothesis: a critical review. International Journal of Alzheimer's Disease, 2012, Article ID 369808.

    • National Center for Biotechnology Information (NCBI) Bookshelf reference: https://www.ncbi.nlm.nih.gov/books/NBK3885/